Möchten Sie immer auf dem neuesten Stand bleiben?

ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001 AS A NOVEL IMMUNO-MODULATORY THERAPY FOR VIRAL-INDUCED EXACERBATION IN ASTHMA Phase IIa clinical study to commence in patients with severe...

ASTRAZENECA TO PRESENT NEW DATA FROM ITS BROAD PORTFOLIO IN WIDE RANGE OF PATIENT POPULATIONS AT THE AMERICAN DIABETES ASSOCIATION 74TH SCIENTIFIC SESSIONS® 43 abstracts on approved products and an...

ASTRAZENECA UPDATES ON THE RAPID PROGRESS OF ITS ONCOLOGY PIPELINE AT ASCO 2014 The following amendment has been made to the 'ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO' announcement released...

AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 May 2014, as compelling data from over 40 scientific abstracts related to...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION STATEMENT REGARDING PFIZER...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION CLARIFICATION REGARDING PFIZER STATEMENT 20 May...

ASTRAZENECA BOARD REJECTS PFIZER’S FINAL PROPOSAL Final Proposal falls short of AstraZeneca's value as an independent science-led company AstraZeneca has excellent momentum in the delivery of its...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Continuing Progress in accelerating late stage...

ASTRAZENECA TO DEMONSTRATE THE STRENGTH AND RAPID ACCELERATION OF ITS ONCOLOGY PIPELINE AT ASCO 2014 Preliminary data* released ahead of full data presentations at ASCO, 30 May-3 June New data from...

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation. The...